Shukra Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2025 ,inter alia, to consider and approve 1. Unaudited financial ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Shukra Pharmaceuticals has informed BSE that its Board of Directors will meet on August 13, 2025, at the registered office. The main agenda is to consider and approve the unaudited financial results for the quarter ended June 30, 2025 (Q1 FY26), along with the limited review report from the statutory auditor. Apart from this, the board may take up any other business with the Chairman's permission. The trading window for dealing in company securities is already closed from July 1, 2025, and will reopen 48 hours after the results are declared. No financial figures or business decisions have been disclosed in this intimation — those will come after the board meeting.
This is a routine regulatory filing ahead of the quarterly results announcement. Investors should watch for the actual Q1 numbers on or after August 13, 2025, to assess the company's performance. No immediate stock price impact is expected from this intimation alone.